Skip to main content

Gastroparesis Treatment Market is Growing at Dynamic CAGR of 3.8% During Forecast to 2023


Market Analysis:

Gastroparesis may interfere with normal digestion resulting in vomiting and nausea, and also cause issues with nutrition and blood sugar levels. At times this is a complication of diabetes while there are some that develop it after surgery. Pain in the stomach, lack of appetite, abdominal bloating, gastroesophageal reflux, the feeling of fullness, and nausea are some of the usual symptoms of gastroparesis. 
The global Gastroparesis Treatment Market Size is predicted to touch USD 5,323.62 million at a 3.8% CAGR over the forecast period (2016-2023), in accordance with the latest Market Research Future (MRFR) report. Gastroparesis means stomach paralysis.


There are several causes of gastroparesis, of which diabetes is the most common. Other causes include upper intestinal tract surgery, some chemotherapy agents, radiation treatment applied over the abdomen or chest, certain cancers, eating disorders, psychological conditions, idiopathic causes, neuromuscular diseases, autoimmune conditions, connective tissue disorder such as scleroderma, endocrine disorders such as hypothyroidism, and infections. 
Various factors are propelling the gastroparesis treatment market growth. These factors, in accordance with the MRFR report, include the focus of key market players in R&D for launching specific drugs to treat gastroparesis, the introduction of new drugs, increasing number of surgeries resulting in post-operative gastroparesis, and increasing prevalence of diabetes mellitus. 

Key Players :
·         Rhythm Pharmaceuticals
·         Evoke Pharma
·         Alfa Wassermann SPA
·         Cardinal Health
·         Janssen Global Services
·         C. R. Bard
·         Boston Scientific Corporation
·         Salix Pharmaceuticals
·         Abbott Laboratories
·         Kimberly-Clark Corporation
·         Medtronic

Market Segmentation:

·         The MRFR report provides a complete segmental analysis of the gastroparesis treatment market report on the basis of type, drug class, and treatment. 

·         Based on gastroparesis type, the gastroparesis treatment market is segmented into post-surgical, diabetic, idiopathic, and others. Of these, the idiopathic gastroparesis will have the largest share in the market over the forecast period. 

·         Based on drug class, the gastroparesis treatment market is segmented into antidepressants, antiemetics, prokinetic drugs, and others. Of these, the prokinetic drugs segment will dominate the market over the forecast period. This is owing to its ease of availability, effectiveness, increasing applicability and high usage to treat gastroparesis. 

·         Based on treatment, the gastroparesis treatment market is segmented into parenteral nutrition, gastric electric stimulation, and jejunostomy. 

Regional Analysis:
By region, the gastroparesis treatment market report covers the latest trends and growth opportunities across Europe, the Americas, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, the Americas will remain at the forefront in the market over the forecast period. This is owing to the region’s good reimbursement scenario and constant technological advancement. Moreover, an increase in the number of diabetic patients in the region is also boosting the market growth. Diabetic gastroparesis is a major type of gastroparesis that is affecting the population in this region. 

The gastroparesis treatment market in Europe is predicted to have the second-largest share in the market over the forecast period, but the sluggish economy in this region is predicted to restrict the market growth. 

The gastroparesis treatment market in the APAC region is predicted to grow at the highest CAGR over the forecast period. This is owing to unmet needs, larger patient population, rise in product approvals, and government focus to improve health care facilities. 

The gastroparesis treatment market in the MEA will have slow growth in the market over the forecast period. 
NOTE : Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Labels:

Comments

Post a Comment

Popular posts from this blog

Covid 19 Analysis on Respiratory Therapeutic Devices Market Analysis and Forecast to 2023

Market Overview: The Global Respiratory Therapeutic Devices Market is predicted to scale to new heights and expand at a CAGR of 10.8% over the forecast period of 2017-2023, asserts Market Research Future (MRFR) in an in-depth study.                   The growth of the Global Covid 19 Analysis on Respiratory Therapeutic Devices Market Analysis   is primarily led by the recent surge in the incidence of chronic respiratory diseases such as asthma, COPD, and sleep disorder breathing. As per the estimates of the World Health Organization (WHO), approximately 235 Mn people suffered from asthma in 2017 across the globe. The growing burden of chronic respiratory diseases (CRDs) induces strong demand for respiratory therapeutic devices within the market. Moreover, with the increase in the global aging population, there is a greater need for respiratory therapeutic devices.     ...
Post a Comment
Read more

Antibody Drug Conjugate Market is Presumed to Grow at a Reliable CAGR of 19% During Forecast to 2023

Antibody Drug Conjugate Market Analysis: Various factors are adding to the global antibody drug conjugate market share. These factors, as per the new MRFR report, include advances in medical technology, rising cases of cancer, growing obese population, and increasing aging population. Additional factors adding market growth include increasing collaborations between biotechnology companies, biopharmaceuticals, and research institutes, rising R&D on oncology diseases, increasing research on advanced drug discoveries, rising number of research on antibody therapies, and preclinical research. The global Antibody Drug Conjugate Market Share is likely to grow at a 19% CAGR between 2017- 2023 , reveals the new Market Research Future (MRFR) report. Antibody drug conjugates are new-age therapeutic agents that have three parts- a chemical linker to attach cytotoxic agents to antibodies, cytotoxic agents for killing target cancer cells, and specific antibodies for binding. Lymphoma, mult...
Post a Comment
Read more

Desalting and Buffer Exchange Market is Growing at a Healthy CAGR of 10.5% During Forecast to 2023

Market Highlights: The Global Desalting and Buffer Exchange Market is anticipated to have held a market value of USD 615.20 million in the year 2017 and is expected to grow at a CAGR of 10.5% during the forecast period. Desalting and buffer exchange play a key role in biotechnological companies. Buffer exchange is used to place a protein solution into a more suitable buffer before applications such as electrophoresis, ion exchange, affinity chromatography among others. Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/6633 Buffer exchange is the term used when one set of buffer salts in a sample is exchanged by another more appropriate buffer set. The rising demand for monoclonal antibodies, growing research and development expenditure by the biopharmaceutical companies, and rising focus on proteomic and genomic research is anticipated to boost the growth of the market over the forecast period. However, the dearth of skilled professionals is excepted to ...
Post a Comment
Read more